MD BABU MIA

ASSISTANT PROFESSOR

Icahn School of Medicine at Mount Sinai

United States

Research Interests

Explore related searches

Professors in United States

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

MD Babu Mia is an Assistant Professor at the Icahn School of Medicine at Mount Sinai, United States. His research primarily focuses on myelofibrosis and myeloproliferative neoplasms, with recent articles addressing topics such as thrombocytopenia, the impact of genetic abnormalities, and immune checkpoint inhibitor therapy in cancer. His work contributes to the understanding of hematologic recovery and the molecular consequences of mutations in hematopoietic stem cells.

Articles (10)

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Collaborators (2)

Christian Salib

Assistant Professor, Assistant Director of Hematopathology Services

Icahn School of Medicine at Mount Sinai

UNITED STATES

View details

Ronald Hoffman

Medical Doctor/Professoe

Icahn School of Medicine at Mount Sinai

UNITED STATES

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

MD BABU MIA

Research Interests

Explore related searches

Contact this professor

About

Articles (10)

Thrombocytopenia in myelofibrosis is characterized by inflammatory megakaryocytes with reduced G6B expression

HMGA2 overexpression with specific chromosomal abnormalities predominate in CALR and ASXL1 mutated myelofibrosis

THROMBOCYTOPENIA IN MYELOFIBROSIS (MF) IS CHARACTERIZED BY INFLAMMATORY MEGAKARYOCYTES WITH REDUCED G6B EXPRESSION THROMBOCYTOPENIA IN MYELOFIBROSIS IS CHARACTERIZED BY INFLAMMATORY MEGAKARYOCYTES WITH REDUCED G6B EXPRESSION

Role of HMGA2 Overexpression Caused By Specific Genetic <i>HMGA2</i> Aberrations in Disease Progression in Calreticulin-Mutated Myelofibrosis Patients

Molecular Consequences and Targeting of PPM1D Mutations and Overexpression in Myeloproliferative Neoplasm Stem Cells

Selinexor Depletes Ruxolitinib Refractory Myelofibrosis Hematopoietic Stem Cells By Inducing Apoptosis and Blunting the Pro-Inflammatory Milieu

A Dual-Specific Inhibitor of Rock/Aurk, RR-1752, for Primary Myelofibrosis

Inflammatory Marker Levels, Age, Race and Prior Treatment Burden Independently Predict Delayed Hematologic Recovery after BCMA-Directed CART Therapy in Multiple Myeloma

Immune Checkpoint Inhibitor Therapy in Cancer: Success versus Limitations

Comprehensive Characterization of Prolonged Unexplained Cytopenias in Relapsed/Refractory Multiple Myeloma Patients Following BCMA-Directed CAR-T Cell Therapy

Collaborators (2)

Christian Salib

Ronald Hoffman

Make your next move.